Time to hop on board Acasti Pharma, says Mackie Research

Jul 02 17:07 2019 Print This Article

With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti Pharma News, Stock Quote, Chart TSXV:ACST) is ready for liftoff, says Mackie Research Capital Corporation analyst André Uddin. On Thursday, Uddin reiterated his “Speculative Buy” rating and $8.70 target price for Acasti, representing a projected 12-month return of 469 per cent […]

The post Time to hop on board Acasti Pharma, says Mackie Research appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Columbia Care is deeply undervalued: Beacon Securities

US cannabis play Columbia Care (Columbia Care Stock Quote, Chart, News NEO:CCHW) gets a positive review from Beacon Securities analyst Russell Stanley on its announcement of a collaboration with a UK pharmaceutical manufacturer for the import of Columbia’s proprietary BeneCeed CBD tablet. In an u ...

Caisse investing in Mexican pharmaceutical company

The Caisse de dépôt et placement du Québec is investing US$500 million in Laboratorios Sanfer, an independent Mexican pharmaceutical company. The company, which currently maintains a ... ...

Tech Talk for Tuesday August 20th 2019

  StockTwits released yesterday @EquityClock Vertex Pharmaceutical $VRTX, a NASDAQ 100 stock moved above $186.33 setting an intermediate uptrend. Dollarama $DOL.CA, a TSX 60 stock moved above $50.74 extending an intermediate uptrend.   Trader’s Corner   Equity Indices and related ETFs Daily ...

Opportunities for Generic Drug Development

Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about the sustainability and profitability of major generics companies. But some… The post Opportunities for Generic Drug Development appeared first on DrugPatentWatch - Make ...

Week Ahead: With Nifty Vulnerable At Higher Levels, These Sectors May Act As Safe Havens

With a 3-day working week, the markets moved along expected lines and stayed within a limited range. As anticipated, the NIFTY did not make any directional move, remaining within the 50-Week MA and 100-Week MA (as mentioned in our previous weekly note). After flirting with the 50-Week MA, which sta ...

Answers to popular stock and investing questions this week

This week we look at some of the most popular questions in the 5i Research question and answer service featuring Canopy Growth, Preferred Shares, and high interest savings accounts. ...

Profound Medical is ready for a breakout, says Mackie Research

Investors should soon expect a breakout for Profound Medical Corp (Profound Medical Corp Stock Quote, Chart, News TSX:PRN) after the company’s just-received FDA clearance for its TULSA-PRO medical device, says analyst Andre Uddin with Mackie Research Capital Corporation. The analyst provided an u ...

Canopy Growth Corp has lost its lead, GMP says

Following a quarter that came in softer than expected, GMP Securities analyst Ryan Macdonell has cut his price target on Canopy Growth Corp (Canopy Growth Corp Stock Quote, Chart, News TSX:WEED) On Wednesday, Canopy reported its Q1, 2020 results. The company lost $1.28-billion on net revenue of $90 ...

Canopy Growth Corp has price target slashed at PI

Canadian cannabis licensed producer Canopy Growth  (Canopy Growth  Corp Stock Quote, Chart, News TSE:WEED) got a big target price cut from PI Financial’s Jason Zandberg on the back of the company’s disappointing quarterly report. In an earnings update on Thursday, Zandberg kept his “Buy” ...

ProMetic Life Sciences has price target slashed at Echelon

Considerable losses and extended timelines for drug approval are keeping ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News TSX:PLI) a “Hold” for analyst Douglas Loe of Echelon Wealth Partners, who in a client update on Tuesday dropped his price target from $15.00 to $9.25 ...